Mangoceuticals, Inc. (NASDAQ:MGRX) CEO Jacob D. Cohen Purchases 275,000 Shares of Stock
Mangoceuticals, Inc. (NASDAQ:MGRX) CEO Jacob D. Cohen Purchases 275,000 Shares of Stock
Mangoceuticals, Inc. (NASDAQ:MGRX – Get Rating) CEO Jacob D. Cohen purchased 275,000 shares of the firm's stock in a transaction dated Monday, April 10th. The shares were acquired at an average cost of $1.00 per share, with a total value of $275,000.00. Following the completion of the purchase, the chief executive officer now directly owns 8,275,000 shares in the company, valued at $8,275,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Mangoceuticals Stock Performance
NASDAQ:MGRX opened at $1.03 on Wednesday. Mangoceuticals, Inc. has a 1-year low of $0.86 and a 1-year high of $4.37.
Get Mangoceuticals alerts:Mangoceuticals Company Profile
(Get Rating)
Mangoceuticals Inc is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc is based in DALLAS, TX.
See Also
- Get a free copy of the StockNews.com research report on Mangoceuticals (MGRX)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM's Hot Hand Is All In For A Rally, After This Small Break
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Mangoceuticals, Inc. (NASDAQ:MGRX – Get Rating) CEO Jacob D. Cohen purchased 275,000 shares of the firm's stock in a transaction dated Monday, April 10th. The shares were acquired at an average cost of $1.00 per share, with a total value of $275,000.00. Following the completion of the purchase, the chief executive officer now directly owns 8,275,000 shares in the company, valued at $8,275,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Mangoceuticals, Inc.(纳斯达克股票代码:MGRX — 获取评级)首席执行官雅各布·科恩在4月10日星期一的交易中购买了该公司27.5万股股票。这些股票的收购平均成本为每股1.00美元,总价值为275,000.00美元。收购完成后,首席执行官现在直接拥有该公司的827.5万股股票,价值827.5万美元。此次收购是在向美国证券交易委员会提交的法律文件中披露的,该文件可通过以下方式获得 美国证券交易委员会网站。
Mangoceuticals Stock Performance
Mangoceuticals 股票表现
NASDAQ:MGRX opened at $1.03 on Wednesday. Mangoceuticals, Inc. has a 1-year low of $0.86 and a 1-year high of $4.37.
纳斯达克股票代码:MGRX周三开盘价为1.03美元。Mangoceuticals, Inc.的1年低点为0.86美元,为1年来的最高水平,为4.37美元。
Mangoceuticals Company Profile
Mangoceuticals 公司简介
(Get Rating)
(获取评级)
Mangoceuticals Inc is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc is based in DALLAS, TX.
Mangoceuticals Inc通过安全的远程医疗平台参与开发、营销和销售各种男性健康和保健产品,包括其独特配方的勃起功能障碍药物品牌 “Mango”。Mangoceuticals Inc. 总部位于德克萨斯州达拉斯。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Mangoceuticals (MGRX)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM's Hot Hand Is All In For A Rally, After This Small Break
- 免费获取 StockNews.com 关于 Mangoceuticals(MGRX)的研究报告的副本
- 利率上升时银行股会上涨吗?
- 如何投资垂直农业股票
- Can-Fite BioPharma 在胰腺癌抑制发现上大放异彩
- Ecolab:Slow and Steady 赢得了比赛
- 在这次短暂的休息之后,米高梅的 Hot Hand 全力以赴准备拉力赛
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Mangoceuticals Daily 的新闻和收视率 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Mangoceuticals及相关公司最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧